Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

NAFLD - Non-Alcoholic Fatty Liver Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for NAFLD - Non-Alcoholic Fatty Liver Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 2 NAFLD - Non-Alcoholic Fatty Liver Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Changi General Hospital (1), Tasly Biopharmaceuticals Co., Ltd. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is OneSTOP program (behavioral, 1 trial), followed by Standard of care weight management program, B1344.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track NAFLD - Non-Alcoholic Fatty Liver Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06890169

OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities

The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic...

Sponsor: Changi General HospitalEnrolling: 1201 location
RECRUITINGPhase 1NCT07128797

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients...

This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and...

Sponsor: Tasly Biopharmaceuticals Co., Ltd.Enrolling: 325 locations

Frequently Asked Questions

There are currently 2 clinical trials for NAFLD - Non-Alcoholic Fatty Liver Disease, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for NAFLD - Non-Alcoholic Fatty Liver Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for NAFLD - Non-Alcoholic Fatty Liver Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.